

Published in final edited form as:

Nat Commun. 2013 ; 4: 1629. doi:10.1038/ncomms2624.

Impaired endolysosomal function disrupts Notch signaling in optic nerve astrocytes

Mallika Valapala¹, Stacey Hose¹, Celine Gongora², Lijin Dong³, Eric F. Wawrousek³, J. Samuel Zigler Jr.¹, and Debasish Sinha^{1,*}

¹The Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland, U.S.A

²IRCM INSERM U896, 208, rue des Apothicaires, Montpellier, Cedex 5, France

³The National Eye Institute, National Institutes of Health, Bethesda, Maryland, USA

Abstract

Astrocytes migrate from the optic nerve into the inner retina, forming a template upon which retinal vessels develop. In the *Nucl1* rat, mutation in the gene encoding β A3/A1-crystallin disrupts both Notch signaling in astrocytes and formation of the astrocyte template. Here we show that loss of β A3/A1-crystallin in astrocytes does not impede Notch ligand binding or extracellular cleavages. However, it affects V-ATPase activity, thereby compromising acidification of the endolysosomal compartments, leading to reduced γ -secretase-mediated processing and release of the Notch intracellular domain (NICD). Lysosomal-mediated degradation of Notch is also impaired. These defects decrease the level of NICD in the nucleus, inhibiting expression of Notch target genes. Overexpression of β A3/A1-crystallin in those same astrocytes restored V-ATPase activity and normal endolysosomal acidification, thereby increasing the levels of γ -secretase to facilitate optimal Notch signaling. We postulate that β A3/A1-crystallin is essential for normal endolysosomal acidification, and thereby, normal activation of Notch signaling in astrocytes.

Notch signaling is involved in numerous functions including pattern formation during development and gliogenesis^{1,2}. The Notch pathway is evolutionarily conserved and promotes the generation of astrocytes from neuronal precursor cells^{3,4}. Four Notch receptors, Notch1-4, have been identified. The Notch gene encodes a single-pass transmembrane protein which appears on the cell surface as a heterodimeric protein after maturing along the secretory pathway⁵. Notch receptors are activated by interaction with transmembrane ligands expressed on the surface of juxtaposed cells. Binding of the ligands activates two sets of proteolytic cleavages in the Notch receptor. First, TNF α -converting enzyme (TACE), a member of the ADAM family of matrix metalloproteases, cleaves the receptor at its extracellular domain, generating a membrane-tethered Notch receptor⁵. Next, the receptor is cleaved within its transmembrane domain by the γ -secretase multiprotein complex (including presenilin, nicastrin, APH1 and PEN2)⁶, resulting in release of the

*Corresponding Author: Debasish Sinha, The Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, 410-502-2100, 410-614-6728 (fax), Debasish@jhmi.edu.

AUTHOR CONTRIBUTIONS

MV conducted the experiments, participated in the study design and analyzed data. SH constructed figures for the manuscript and performed some initial experiments. CG contributed to the transcriptional studies. LD and EFW participated in the generation of *Cryba1* floxed mice. SZ participated in the study design and analyzed data. DS designed the study and assisted with the generation of *Cryba1* floxed mice and data analysis. MV, SZ and DS wrote the paper. All authors have approved the final manuscript.

COMPETING FINANCIAL INTERESTS

The authors declare no competing financial interests.

Notch intracellular domain (NICD); NICD translocates to the nucleus to activate Notch target genes ⁷.

The activation of Notch requires processing, endocytosis and trafficking of both Notch receptor and ligand. Ubiquitination has an important role in the activation of Notch signaling ⁸. In recent years, it has also been suggested that endocytosis of Notch is important for ligand-mediated activation ^{9, 10}. There is now a general consensus that γ -secretase-mediated S3 cleavage of Notch can occur at multiple steps within the endolysosomal compartments ¹¹. Increasing evidence suggests that endocytosis is involved in the transport of ligand-receptor complexes to acidic endolysosomal compartments, where low pH is required for signaling ^{10, 12}. The acidic luminal environment of endosomes, lysosomes and secretory vesicles is established by the vacuolar-type proton ATPase (V-ATPase), which pumps protons into the lumen ¹³⁻¹⁵. V-ATPase-dependent acidification is required to optimally activate γ -secretase, an acid protease that mediates S3 cleavage of Notch ¹⁵. Therefore, progressive acidification of the endolysosomal system could influence the levels of NICD production. In *Drosophila*, various mutants that show impaired acidification due to alteration of V-ATPase activity affect Notch signaling ^{13, 15}.

In the past decade, several laboratories have shown that crystallins, the major structural proteins of the lens, are expressed outside of the lens and have cellular functions ¹⁶⁻¹⁸. We previously postulated that β A3/A1-crystallin, may regulate the process of programmed cell death in the developing retina and that it also plays a pivotal role in maintaining the proper number of astrocytes in the retina through an anoikis-mediated cell death process ^{19, 20}. We show here that β A3/A1-crystallin affects Notch signaling in astrocytes by regulating endolysosomal function in astrocytes by modulating the activity of V-ATPase. In the absence of β A3/A1-crystallin, V-ATPase activity decreases and acidification of endolysosomal compartments is impaired. The higher pH inhibits the γ -secretase-mediated formation of NICD, leading to decreased Notch signaling.

RESULTS

Optic nerve astrocytes express both Notch1 and Jagged1

Notch signaling plays an important role during differentiation and maturation of brain astrocytes ^{21, 22}; however, its role in optic nerve astrocytes is unexplored. Disrupted Notch signaling affects pattern formation in other systems ²³. We have shown major defects in template formation and honeycomb patterning by Nuc1 retinal astrocytes with mutated β A3/A1-crystallin ^{24, 25}. We first studied expression of Notch pathway components in optic nerve astrocytes cultured from 2–3 day old WT (wild type) and Nuc1 rats. Quantitative reverse transcriptase PCR (qRT-PCR) analysis showed that WT cells strongly express Notch1 receptor transcript (Figure 1a) with trace levels of Notch4 (data not shown). Nuc1 cells have 2 fold higher expression of Notch1 than WT cells. The canonical Notch ligands are single pass transmembrane proteins belonging to the Delta-like or serrate families. Using specific primers, we tested their expression in WT and Nuc1 astrocytes. Our results show, for the first time, that optic nerve astrocytes express Jagged1 (Figure 1b, c), with no significant expression of the Delta-like ligands. Co-localization of Jagged1 with the astrocyte marker, glial fibrillary acidic protein (GFAP), in retinal flatmounts confirms expression of Jagged1 in retinal astrocytes (Figure 1d).

Next, we investigated the expression of NICD using anti-Notch V1744, an antibody specific for NICD. Immunostaining and western blotting detected a significant decrease in NICD protein in Nuc1 astrocytes compared to WT (Figure 1e, f). Confocal microscopy (Figure 1g) demonstrated that NICD (red) staining was primarily nuclear and weaker in Nuc1 astrocytes compared to WT, while Jagged1 (green) staining was similar in both cell types.

Notch signaling is reduced in Nuc1 astrocytes

Since our data indicate downregulation of NICD in Nuc1 astrocytes, we examined activation of the Notch pathway using a Notch-luciferase reporter assay. Notch1 receptor constructs, including a full-length receptor (Notch-FL) and truncated or mutant derivatives with varying activation profiles, were used. A constitutively active Notch construct, N δ E, activates the Notch pathway in a ligand-independent manner, and the NICD construct contains only the Notch intracellular domain. WT and Nuc1 astrocytes were co-transfected with Notch-FL, N δ E or NICD constructs, along with the 6XCBF1-luciferase Notch reporter plasmid, and the pRL-SV40 Renilla luciferase reporter plasmid. WT astrocytes, transfected with the NotchFL construct, showed 4-fold increased activity compared to astrocytes transfected with vector only (Figure 2a). Nuc1 astrocytes, in contrast, showed only minimal activation (Figure 2b). The Notch pathway was activated equally in WT and Nuc1 astrocytes expressing the constitutively active N δ E construct (Figure 2a, b). Furthermore, similar activation was observed in WT and Nuc1 astrocytes expressing the NICD construct (not shown). Notch1 in WT astrocytes was strongly activated (~65% increase in luciferase activity compared to untreated cells) by EDTA, a Ca²⁺-chelating agent which activates Notch in a ligand-independent manner²⁶. This activation was inhibited by N-[N-(3, 5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT), an inhibitor of γ -secretase (Figure 2a). Nuc1 astrocytes, however, showed only modest activation of the Notch pathway by EDTA, although DAPT did inhibit this Notch activation (Figure 2b). EDTA did not significantly influence Notch activity in either WT or Nuc1 astrocytes expressing N δ E, although DAPT still was inhibitory (Figure 2a, b). DMSO (vehicle for DAPT) did not affect Notch activity in WT or Nuc1 astrocytes.

We also assessed the expression of Notch target genes using qRT-PCR. Expression of Hes1 and Hey1, was reduced ~65% and ~75% respectively; in Nuc1 astrocytes compared to WT astrocytes (Figure 2c, d).

Jagged1 is an agonist of Notch signaling in astrocytes

Our studies have shown that optic nerve astrocytes strongly express Jagged1. Previous studies have shown that Jagged1 acts as an inhibitor of the Notch signaling pathway by competitively inhibiting binding of Delta-like ligands to the Notch receptor^{27, 28}. Therefore, we sought to determine whether Jagged1 acts as agonist or antagonist in astrocytes. WT and Nuc1 astrocytes were treated with Jagged1 siRNA, and Notch pathway activity monitored by measuring expression of Hey1 and Hes1. siRNA knockdown of Jagged1 (Figure 3a) resulted in concomitant reductions in Hes1 and Hey1, in both WT and Nuc1 astrocytes (Figure 3b).

To study the Jagged1-mediated activation of Notch signaling, we used a co-culture system, where cells expressing full length Notch1 receptor and the 12XCSL-luciferase Notch reporter and pRL-CMV renilla plasmids were interfaced with cells expressing full length Jagged1. We observed robust 12XCSL-luciferase activation in WT cells, whereas Nuc1 cells showed much weaker activation of the Notch pathway (Figure 3c). As control, a vector expressing a mutant Jagged1 protein that fails to bind to the Notch receptor (Jagged1 Δ EGF) was used. This resulted in an abrogation of Notch signaling, suggesting that the trans-interactions with Jagged1 expressing cells were inhibited.

Since optic nerve astrocytes express both Notch1 and Jagged1, we next asked whether the Notch receptor is cis-inhibited by ligand expressed in the same cell and trans-activated by ligand expressed on neighboring cells. In most cancer cells, Notch receptor and ligand are expressed by the same cell, with the ligand inhibiting the receptor, thereby facilitating the receptor trans-interaction with ligand expressed by neighboring cells²⁹. We studied the

trans-interactions by silencing Jagged1 expression using siRNA and transfecting the same cells with the 12XCSL-luciferase Notch reporter plasmid and pRL-CMV Renilla plasmid. Figure 3d shows significant induction of Notch signaling in both WT and Nuc1 astrocytes, suggesting a cis-inhibition of the receptor by Jagged1 in the same cell and trans-activation by Jagged1 on neighboring cells. Cells transfected with non-targeting siRNA were also co-cultured with Jagged1 overexpressing cells, showing only a modest induction of the Notch pathway in WT, and none in Nuc1 astrocytes (Figure 3d).

Defective S3 cleavage decreases NICD in Nuc1 astrocytes

Our data show that NICD is decreased in Nuc1 cells despite the higher levels of Notch1 receptor. Since this could result from defective proteolytic cleavage of Notch, we analyzed the two cleavage steps required for Notch activation. The S2 and S3 cleavages are mediated by ADAM metalloprotease and γ -secretase, respectively⁵. In cells treated with a hydroxamate ADAM inhibitor, BB-94, the mRNA expression of Notch targets Hes1 and Hey1 was inhibited in both WT and Nuc1 cells (Figure 4a). To confirm cleavage of the Notch receptor, we used a myc-tagged, constitutively active, membrane-bound derivative of Notch1 (N δ E). Cleavage of N δ E at V1744 by γ -secretase generates a product corresponding to NICD. This construct was visualized by immunoblotting with anti-Myc antibody. In both WT and Nuc1 optic nerve astrocytes expressing N δ E, an approximately 85-kDa protein representing uncleaved N δ E and a 75 kDa band corresponding to NICD were detected.

To confirm the identity of these fragments, WT and Nuc1 astrocytes were first transfected with a N δ E construct mutated at residue 1744 (V1744K) to prevent cleavage and generate a band co-migrating with the higher-molecular-mass N δ E band. Further, astrocytes transfected with an N δ E-derived construct truncated at the cleavage site (ICv1744), produced a fragment co-migrating with NICD (Figure 4b&c). Since both the cleaved and uncleaved forms were generated in Nuc1 astrocytes expressing N δ E, the cleavage sites of Notch1 are functional in the mutant astrocytes.

NICD translocation occurs normally in Nuc1 astrocytes

We next investigated whether nuclear translocation of NICD is inhibited in Nuc1 astrocytes. For this, we overexpressed NICD in WT and Nuc1 astrocytes using a constitutively active Notch1 construct in a pCDNA3.1 plasmid. Overexpression was confirmed by western analysis (Figure 5a). Increased staining for NICD was seen in both WT and Nuc1 astrocytes compared to astrocytes transfected with vector alone (Figure 5b). qRT-PCR showed that overexpression of NICD by Nuc1 astrocytes strongly rescued expression of Notch target genes (Figure 5c). The expression of Hey1 and Hes1 was also measured in WT and Nuc1 cells transfected with Notch-FL and Notch extracellular truncation (NEXT) plasmids. In contrast to overexpression of NICD, neither of these constructs rescued Hey1 or Hes1 expression in Nuc1 astrocytes (Figure 5d, e).

β A3/A1-crystallin regulates γ -secretase activity

γ -Secretase is enzymatically more active in the low pH environment of the endolysosomal compartments^{9, 30}. In the case of Amyloid Precursor Protein, a well characterized γ -secretase substrate, cleavage to produce β amyloid occurs in the endolysosomal compartments³¹. To determine if the activity and sub-cellular distribution of γ -secretase is aberrant in Nuc1 astrocytes, post-nuclear supernatants from WT and Nuc1 astrocytes were layered on iodixanol gradients and subjected to ultracentrifugation. The composition of the fractions was determined by immunoblotting with specific markers. Lysosome-associated membrane protein1 (LAMP1)-positive lysosomes were strongest in fractions 3, 4, and 5; Rab5-positive endosomes in fractions 6, 7, and 8; and Golgi in fractions 9 and 10 (Figure 6a). The activity of γ -secretase was measured by performing ELISA to quantify production

of β -amyloid 40. In WT astrocytes, γ -secretase activity (Figure 6b) was present in fractions 3, 4, and 5 corresponding to the lysosomes; fractions 6, 7, and 8 corresponding to the Rab5-positive endosomes. We also detected modest activity in the Golgi. Nuc1 astrocytes showed significantly decreased γ -secretase activity in the endolysosomal compartments, whereas activity in the Golgi was relatively unchanged (Figure 6c). Overexpression of β A3/A1-crystallin in Nuc1 astrocytes restored normal γ -secretase activity (Figure 6d). To confirm that β A3/A1-crystallin modulates γ -secretase activity in astrocytes, we performed *Cryba1* siRNA silencing studies to downregulate β A3/A1-crystallin in WT rat astrocytes in culture using specific ON-TARGET plus SMART pool siRNA (Dharmacon, CO). Scrambled siRNA was used as control. β A3/A1-crystallin downregulation was confirmed at the mRNA level by quantitative PCR analysis and at the protein level by immunoblotting (data not shown). Knockdown of β A3/A1-crystallin in WT astrocytes decreases γ -secretase activity, but the decrease is not as robust as in Nuc1 homozygous astrocytes, the activity could be rescued to normal levels by subsequent overexpression of β A3/A1-crystallin (Supplementary figure S1). As proof of principle that β A3/A1-crystallin can modulate γ -secretase activity in astrocytes, we used Nuc1 heterozygote astrocytes in culture and downregulated β A3/A1-crystallin with siRNA as above. The concentration of siRNA required to downregulate *Cryba1* in Nuc1 heterozygotes was significantly lower than that needed with WT astrocytes. Heterozygote astrocytes in which *Cryba1* was downregulated showed loss of γ -secretase activity to levels similar to that in Nuc1 homozygous astrocytes. Activity was rescued by overexpression of β A3/A1-crystallin in the same cells (Figure 6e). In addition, *Cryba1* floxed mice were generated (Supplementary figure S2); downregulation of β A3/A1-crystallin in astrocytes cultured from these mice, using an adenoviral vector expressing Cre-recombinase, also decreased γ -secretase activity, however, this activity was rescued by subsequent over-expression of β A3/A1-crystallin (Figure 6f). γ -Secretase activity was also decreased in endolysosomes of both WT and Nuc1 astrocytes pre-treated with chloroquine, an inhibitor of lysosomal acidification (Supplementary figure S3). The decrease in activity was more significant in WT astrocytes than in Nuc1. γ -Secretase activity was not affected in Golgi, a non-acidic compartment. Previous studies, and our results, indicate a stringent pH requirement for γ -secretase activity^{12, 31, 32}. While low levels of γ -secretase activity are detectable in Nuc1 astrocytes, that activity may be insufficient for optimal Notch signaling. Previous studies in other systems have shown that treatment with DAPT resulted in a marked decrease in the generation of NICD, as monitored by expression of Hey1 and Hes1^{5, 33}. qRT-PCR analysis revealed that DAPT treatment reduced Hes1 and Hey1 similarly in WT and Nuc1 cells (Supplementary figure S4).

β A3/A1-crystallin affects V-ATPase activity

Since γ -secretase activity is compromised in astrocytes lacking functional β A3/A1-crystallin, we suspected that endolysosomal acidification might be dysregulated. To obtain direct evidence that this may be the case, we compared V-ATPase activity in astrocytes lacking β A3/A1-crystallin with WT. Isolated lysosomes were incubated in acridine-orange and accumulation of protonated acridine in the lysosomes measured by the resultant fluorescence. In the presence of exogenous ATP, H⁺ uptake was significantly increased in the lysosomes of WT astrocytes. Under the same conditions, the acridine orange fluorescence in Nuc1 astrocytes was significantly lower (Figure 7a). V-ATPase activity in Nuc1 homozygote astrocytes was rescued by β A3/A1-crystallin overexpression (Figure 7b). We further demonstrate reduced V-ATPase activity in β A3/A1-crystallin-downregulated Nuc1 heterozygote astrocytes (Figure 7c), and in astrocytes isolated from *Cryba1* floxed mice, after β A3/A1-crystallin deletion (Figure 7d). Moreover, the V-ATPase activity could be rescued by subsequent overexpression of β A3/A1-crystallin (Figures 7c and 7d). As control, cells were treated with the V-ATPase inhibitor (bafilomycin a1) and significant inhibition of lysosomal V-ATPase activity was observed (data not shown).

Endolysosomal pH was measured by monitoring fluorescence changes in astrocytes loaded with FITC-dextran. In WT the average endolysosomal pH was 4.5, increasing to 5.7 in Nuc1 astrocytes (Figure 7e). This increase in pH was reversed by overexpression of β A3/A1-crystallin in the same cells (Figure 7f). Similarly, loss of β A3/A1-crystallin in Nuc1 heterozygote and *Cryba1*-floxed astrocytes induced alkalinization by ~1pH unit and was rescued to near normal levels by subsequent overexpression of β A3/A1-crystallin in the same astrocytes (Figure 7g&h), suggesting a direct role of β A3/A1-crystallin in regulating acidification of astrocytes.

Degradation of Notch receptor is impaired in Nuc1 astrocytes

Since defective acidification of endolysosomal compartments could also lead to impaired degradation of Notch, we compared the clearance of the Notch receptor in WT and Nuc1 astrocytes after transfection with the Myc-tagged full length Notch1 receptor. To activate the Notch pathway, these cells were co-cultured with cells overexpressing Jagged1. After 1 hour, the myc-tagged Notch1 underwent significant clearance from the cytosol in WT astrocytes. In Nuc1 astrocytes, however, Notch1 strongly persisted. After 3 hours, most of the tagged receptor was degraded in WT, but much remained in the perinuclear region of Nuc1 astrocytes (Figure 8a).

Since degradation of Notch1 appeared dysfunctional in Nuc1 astrocytes, we performed subcellular fractionation using sucrose density gradients. Notch1 was found at interfaces 1 and 2, containing LAMP1 positive lysosomes and Rab5-positive early endosomes, respectively (Figure 8b). The Nuc1 homozygote astrocytes showed greater accumulation of Notch1 in these compartments than did WT astrocytes, suggesting that Nuc1 cells have a compromised ability to degrade and process the Notch receptor. Moreover, overexpression of β A3/A1-crystallin in Nuc1 homozygote astrocytes restored normal lysosomal-mediated degradation of Notch (Figure 8b).

Since Nuc1 results from a mutation in β A3/A1-crystallin, we also determined the subcellular localization of β A3/A1-crystallin in astrocytes. Immunostaining revealed that while β A3/A1-crystallin was predominantly cytosolic in both WT and Nuc1 astrocytes, it also co-localized with LAMP1-positive lysosomes in WT astrocytes and, to a lesser extent, in Nuc1 astrocytes (Figure 8c). Western analysis of the sucrose gradient fractions confirmed these results (Figure 8d).

Our results demonstrate that β A3/A1-crystallin is required for normal lysosomal acidification. To determine if β A3/A1-crystallin also modulates the activity of lysosomal enzymes, we assayed the activity of Cathepsin D, a lysosomal hydrolase requiring low pH for optimal activity. The intermediate chain of Cathepsin D is processed into the active heavy and light chains once the protein encounters the acidic lysosomal environment. Changes in this processing reflect altered function of lysosomal hydrolases. Levels of both the heavy and light chains were decreased in Nuc1 homozygote astrocytes (Figure 8e) and Cathepsin D activity was rescued by overexpression of β A3/A1-crystallin (Figure 8f). Our data also indicate that in Nuc1 heterozygotes and in *Cryba1*-floxed astrocytes, Cathepsin D activity was markedly reduced, while subsequent overexpression of β A3/A1-crystallin rescued activity (Figure 8g&h).

Functional effects of *Cryba1* knockout from *Cryba1*-floxed mouse astrocytes are demonstrated above (Figures 6–8). To prove that Notch signaling is affected, we measured Hes1 and Hey1 expression, finding it decreased in the Cre-infected astrocytes and rescued by subsequent overexpression of β A3/A1-crystallin (Supplementary figure S5).

To determine whether compromise of the ubiquitin-proteasome system in Nuc1 astrocytes might affect Notch degradation, we measured the intracellular levels of the receptor in the presence of specific inhibitors of the ubiquitin proteasomal pathway, clasto-lactacystin β -lactone and MG132³⁴. Treatment with neither inhibitor resulted in a significant accumulation of Notch1 receptor in WT or Nuc1 homozygote astrocytes (Supplementary figure S6). Thus, our results suggest that in astrocytes, endogenous Notch receptor is posttranslationally regulated predominantly by the lysosomal-mediated degradative pathway.

Impaired Notch signaling reduces GFAP promoter activity

Notch signaling has been implicated in the demethylation and activation of the GFAP promoter³⁵. Since GFAP is an important player in astroglial differentiation³⁵ and since the astrocyte template in the Nuc1 homozygote retina is abnormal, we wondered if Nuc1 astrocytes differentiated normally. To determine if Notch is involved in the transcriptional regulation of GFAP in optic nerve astrocytes, we assayed GFAP promoter activity using a GFAP promoter-reporter construct containing the rat GFAP promoter upstream of the firefly luciferase cDNA and the Renilla luciferase reporter under the control of CMV promoter construct. WT and Nuc1 astrocytes were transfected with these constructs and luciferase activity measured as readout for GFAP promoter activity (Supplementary figure S7). WT astrocytes showed a much stronger GFAP promoter activity than did Nuc1 astrocytes. To test whether GFAP promoter activation is due to Notch signaling, we treated cells with DAPT prior to transfecting the cells with the promoter-reporter constructs. Both WT and Nuc1 astrocytes showed a reduction in GFAP reporter activity, confirming the role of the Notch pathway in differentiation of optic nerve astrocytes.

DISCUSSION

The retina requires two macroglial cells, Muller cells and astrocytes, for proper functioning. While Muller cells are retina-specific, astrocytes are present throughout the CNS, and migrate from the optic nerve head into the inner retina³⁶. Our studies with the Nuc1 spontaneous mutant rat, and the work of others, have demonstrated that, in rodents, an astrocyte template is essential for the proper formation of the retinal vasculature^{24, 37–39}. No signaling mechanisms have yet been shown to regulate formation of this template. Notch is the most significantly enriched signaling pathway in developing tissues and is known to regulate pattern formation in other systems; its dysfunction results in various developmental defects and adult pathologies⁴⁰.

We show that optic nerve astrocytes express both the Notch receptor and its ligand, Jagged1. This suggests that in astrocytes, Notch is involved in juxtacrine signaling, where Jagged1 from one astrocyte activates the Notch receptor on a neighboring astrocyte. This juxtacrine signaling may be critical to the proper organization of astrocytes in the developing retina. In Nuc1, defective Notch signaling may account for improper template formation and patterning by retinal astrocytes.

Notch signaling is known to play a pivotal role in cell fate specification during development. For example, it has been shown that blocking Notch signaling causes fewer Muller glial cells to be made in the retina, while an expansion of Muller glial cells was observed when Notch was activated^{41, 42}. Decreased Notch signaling in Nuc1 astrocytes may account for the abnormal morphology and decreased GFAP, that we have reported^{24, 43}. We now show lower gene promoter activity for GFAP in Nuc1 astrocytes, which might potentiate the decreased astrocyte number and abnormal template formation seen in the retinas of Nuc1 rats²⁴, and in transgenic mice overexpressing the mutant β A3/A1-crystallin protein⁴³.

We have previously shown that in retinal pigmented epithelial cells, β A3/A1-crystallin is trafficked to the lysosomes and plays a pivotal role in the degradation of phagocytized photoreceptor outer segments⁴⁴. This prompted us to investigate whether β A3/A1-crystallin modulates Notch signaling by manipulating lysosomal pH in astrocytes. Luminal acidification of endolysosomal compartments is regulated by a major proton pump, V-ATPase⁴⁵. We show that β A3/A1-crystallin may affect endolysosomal acidification by regulating the activity of V-ATPase. Although organelles use the same V-ATPase to acidify their interiors, each is able to maintain a stable, characteristic internal pH⁴⁶. V-ATPase activity is necessary for proper activation of Notch signaling in the endosomal system, although it is not required for Notch to access endosomal compartments¹³. In astrocytes, in which β A3/A1-crystallin is non-functional, the activity of V-ATPase is compromised, diminishing acidification of endolysosomal compartments and resulting in decreased Notch activation. This is consistent with studies showing that normal functioning of V-ATPase is required for optimal catalytic activity of γ -secretase^{45,47}. Loss of functional β A3/A1-crystallin in astrocytes does not impede Notch ligand binding nor extracellular cleavages, because V-ATPase activity is only required after ligand binding. However, loss of β A3/A1-crystallin affects the γ -secretase-mediated processing of NICD in astrocytes. The resultant dysfunction, affecting release of NICD, inhibits transcription of Notch target genes.

Lysosomes are cellular organelles primarily involved in degradation and recycling processes⁴⁸. V-ATPase also plays an important role in the lysosomal degradation of Notch¹⁴. Again, the regulation of proper luminal pH is critical for this process, since the lysosomal hydrolases that degrade internalized proteins, lipids and complex carbohydrates function optimally only in the acidified lysosomal microenvironment¹⁵. Our data on Cathepsin D, one such lysosomal hydrolase, is consistent with a general decrease in lysosomal hydrolase activity in astrocytes lacking β A3/A1-crystallin. In Nuc1 astrocytes, the Notch receptor does not undergo lysosome-mediated degradation at a normal rate, resulting in its abnormal accumulation. Similar results are seen in cells exposed to chloroquine, an inhibitor of lysosomal acidification³⁴. Since ligand-independent Notch activation does not normally occur in mammalian cells when Notch degradation is impaired⁴⁹, acidification of the endolysosomal compartment in astrocytes is essential both for Notch signaling and degradation, suggesting a novel role for β A3/A1-crystallin as an important regulator of this acidification process.

In conclusion, our study describes an unanticipated function for β A3/A1-crystallin in endolysosomal acidification in astrocytes as depicted in the hypothetical model (Figure 8i). Regardless of the specific mechanism whereby mutation of β A3/A1-crystallin affects the activity of V-ATPase, and thus reduces endolysosomal acidification, our data suggest that through its action in maintaining normal lysosomal pH, β A3/A1-crystallin has a fundamental effect on Notch signaling in astrocytes.

METHODS

Antibodies

The following antibodies were used: Notch1 (SAB3300078, Sigma, St. Louis, MO; ab27526, Abcam, Cambridge, MA; H731, Santa Cruz Biotechnology Inc, Santa Cruz, CA), Jagged1 (SC-8303, Santa Cruz Biotechnology Inc), GFAP (Z0334, DAKO Corporation, Carpinteria, CA), Myc (2272S, Cell Signaling Technology, Danvers, MA), LAMP1 (H4A3-C, Developmental Studies Hybridoma Bank, University of Iowa, Iowa), Rab5 (C8B1, Cell Signaling Technology), Calnexin (ab75801, Abcam), Cathepsin D (SC-6487, Santa Cruz Biotechnology).

Knockdown of β A3/A1-crystallin in astrocytes

β A3/A1-crystallin (*Cryba1*) floxed homozygous mice were generated. A BAC clone (Sp6 library, SV129 origin) encompassing the mouse β A3/A1-crystallin locus was obtained through the Invitrogen BAC screening service (Invitrogen, CA) and was used to construct a conditional targeting vector in which exons 4 and 5 were flanked by LoxP sites by recombinering as described⁵⁰. The targeting vector contained a PGK driven DTA (modified diphtheria toxin A) cassette⁵¹ as the negative selection marker, and was electroporated into W4 (129S6/SVEvTac) ES cells⁵². G418-resistant clones were picked, expanded, and screened for homologous recombination by both long-range genomic PCR and Southern blotting. Construction of the targeting vector containing the cKO allele was made as depicted in Supplementary Figure 2. Correctly targeted clones were further analyzed by karyotyping. Embryonic stem cell clones carrying the targeted allele were isolated, and three clones were injected into blastocysts. The selectable marker (frr - Neo^R - frr) was removed by mating to mice (Jackson Laboratories) expressing *flp* recombinase hACTB/FLPe (strain name: B6.Cg-Tg (ACTFLPe) 9205Dym/J) during early development. Successful excision of the selectable marker cassette was confirmed by PCR spanning the insertion site.

Adenovirus Infection

Monolayer astrocytes from *Cryba1* floxed mice were infected with control adenovirus (Ad CMV eGFP) or Cre-recombinase virus (Ad CMV Cre-RSV GFP; KeraFAST Inc, Boston, MA). 10⁴ cells were infected in triplicate at MOI (multiplicity of infection) 0.01–10,000 pfu/cell. Cell survival was assessed 48 hours post infection by MTT assay. Cells infected for 48 hours were transfected with pcDNA3.1-*Cryba1* vector to overexpress β A3/A1-crystallin and harvested 36 hours later.

Primary culture of optic nerve astrocytes

Optic nerve astrocytes from P2 rats (WT and Nuc1) and from P2 *Cryba1* floxed mice were cultured in DMEM-F12 medium containing 10% FBS, as recently described⁵³.

Quantitative reverse transcriptase PCR

2 μ g of total RNA was reverse-transcribed to cDNA in a 20 μ l reaction volume using superscript reverse transcription kit (Invitrogen, Carlsbad, CA). PCR amplification was performed utilizing the 7500 PCR Fast Real-Time System (Applied Biosystems, Carlsbad, CA) with TaqMan probes for Notch1 (Rn01758633_m1), Notch2 (Rn01534371_m1), Jagged1 (Rn00569647_m1), Hey1 (Rn00468865_m1), Hes1 (Rn00577566_m1), NRP1 (Rn00686106_m1), HPRT (Rn01527840_m1) and GAPDH (Rn01775763_g1*). The reaction consisted of the following steps, enzyme activation at 95°C for 20 seconds, 40 cycles of denaturation at 95°C for 3 seconds combined with annealing/extension at 60°C for 30 seconds. All data were analyzed with the ABI 7500 real time PCR system using the data assist software (Applied Biosystems); graphs were plotted using Microsoft Excel. All experiments were performed at least three times in triplicate. Data are represented as mean \pm standard deviation (SD).

Western Blotting

Western blots were done as previously described and quantified by densitometric analysis using ImageJ⁵⁴.

Luciferase assay

For Notch luciferase assays, lipofectamine 2000 (Invitrogen) was used to transfect cells with the different Notch constructs and pGL2-6XCBF-1 Notch luciferase reporter construct (2.3

μg) together with pRL-SV40 (0.1 μg; Promega, Madison, WI) carrying the *Renilla* luciferase gene under the control of the cytomegalovirus promoter. Luciferase activity was measured using a luciferase assay system (Promega). The reporter activity was calculated by normalizing the firefly luciferase value with that of the *Renilla* luciferase control vector and expressed as relative luciferase units. All data were obtained from at least three independent experiments. The relative promoter activities were depicted as the mean ± S.D.

Immunofluorescence of cells and flat mounts

Immunofluorescence was performed on cultured WT and Nuc1 cells and retinal flat mounts as described⁵⁵. Fluorescent images were taken with LSM 510 confocal microscope.

siRNA treatment

WT and Nuc1 astrocytes in 6 well plates were transfected with scrambled, *Cryba1*, or Jagged1 ON-TARGETplus SMARTpool siRNA (Dharmacon, Lafayette, CO).

Plasmids

The Notch expression plasmid NICD was generated by PCR from full length Notch1 cDNA, corresponding to amino acids 1760 to 2556, and was cloned into pcDNA3.1 (Invitrogen). The N8E plasmid encodes the transmembrane and entire intracellular domain of murine Notch1, extending from I1701 to K2530 plus the C-terminal Myc tag in pcDNA3.1 mammalian expression vector (Invitrogen). The constructs N8E, N8E(V1744K), and ICv1744 were kindly provided by Dr. Raphael Kopan and have been described⁵⁶. Jagged1 overexpression plasmid containing a full length rat Jagged1 was cloned into pcDNA3.1. Jagged1 EGF repeats were deleted using site directed mutagenesis. Full-length rat Notch1 cDNA (Notch-FL), containing a single internal Myc epitope tag cloned into the pcDNA3.1. NEXE plasmid was made from the Notch-FL plasmid and NICD plasmid was purchased from Addgene. A GFAP-promoter reporter vector containing 1.9kb of the rat GFAP promoter upstream of the firefly cDNA was cloned into pGL2 vector as previously described³⁵.

Measurement of endolysosomal pH

The luminal pH of endolysosomal vesicles was measured by a ratiometric method using a fluid phase fluorescent marker, fluorescein isothiocyanate (FITC)-conjugated dextran (Invitrogen)⁵⁷. Cells were incubated with FITC-dextran (500 μg/ml, Invitrogen) for 3 hours to allow internalization of the fluorescent probe, then washed and resuspended in 50 mM MES buffer (pH 6.5), and the fluorescence measured at 520 nm by exciting at 450 nm and 495 nm. The fluorescence excitation ratio ($I_{495\text{nm}}/I_{450\text{nm}}$) was calculated, and endosomal pH determined from a calibration curve of FITC-dextran in the pH range of 4 to 7. To generate the calibration curve, cells loaded with FITC-dextran were harvested and resuspended in 10 mM phosphate buffer supplemented with 2 mM FITC-dextran at 2 mg/ml and the measurements were made over time⁵⁸.

Lysosomal V-ATPase activity

For the measurement of lysosomal V-ATPase activity, acridine orange uptake assay was performed with isolated lysosomes⁵⁹. The lysosomes were suspended in buffer containing 6 μM acridine orange (Invitrogen), 150 mM KCl, 2 mM MgCl₂, and 10 mM Bis-Tris-propane. After a steady spectrofluorometric baseline was reached, V-ATPase was activated by addition of ATP (1.4 μM final concentration) and 2.5 μM valinomycin at pH 7.0 to promote the movement of K⁺ from the inside to the outside of the lysosome, generating a membrane potential. Acridine orange uptake is a measure of V-ATPase-driven pumping of hydrogen ions into lysosomes. Fluorescence at 530 nm (excitation at 495 nm) was measured

using a fluorescence plate reader (Bio-Tek Synergy, Winooski, VT). Separately, isolated lysosomes containing the same activation buffer were used to measure the extralysosomal quenching of acridine orange fluorescence. To confirm V-ATPase activity, stimulation of intralysosomal fluorescence and quenching of extralysosomal fluorescence were measured with or without 1 μ M bafilomycin A1 (Sigma).

Subcellular fractionations

To prepare endosomal fractions, cells were homogenized in 1.5 ml of 2 M sucrose in HEPES-EDTA buffer containing protease and phosphatase inhibitor cocktails (Sigma). A postnuclear supernatant (PNS) was prepared by centrifugation at 1,000 \times g at 4°C for 10 min to remove the cell debris, followed by 3,000 \times g for 10 min to remove the nuclei. PNS (0.5 ml) was diluted 1:1 with sucrose (40%) and imidazole (3 mM) solution in HEPES-EDTA buffer. After overlay with 1.5 ml of 35% sucrose with 3 mM imidazole, 1 ml of 25% sucrose with 3 mM imidazole, and 1 ml 8% sucrose with 3 mM imidazole, the sucrose gradients were centrifuged in a SW55 rotor (Beckman, Indianapolis IN) at 150,000 \times g for 90 min. Translucent interfaces were collected from the top of the centrifuge tube.

Cell homogenates were centrifuged at 3000 \times g for 10 min to remove nuclei and at 10,000 \times g for 15 min to remove mitochondria. This supernatant was subjected to density gradient centrifugation and sample collection as described³².

γ -Secretase activity Assay

The iodixanol fractions were incubated with 20 mM Hepes, 150 mM NaCl, 5 mM EDTA, pH 7.0) and 0.4% CHAPSO and a protease inhibitor cocktail (Sigma) at 37°C for 16 h with or without 1 μ M of the γ -secretase inhibitor L-685,458 (Bachem, Torrance, CA). Reactions were stopped by addition of RIPA buffer, heated to 95°C for 5 min and centrifuged at 16,000 \times g for 5 min. Production of A β 40 was analyzed by ELISA with anti-A β 40 antibody according to the manufacturer's protocol (Wako chemicals, Richmond, VA). Production of A β 40 was calculated as A β 40 levels without L-685,458 minus A β 40 levels with added L-685,458. Cells incubated with the lysosomal inhibitor, chloroquine were also used to assay the activity of γ -secretase.

Statistical Analysis

Statistical analysis was performed using Microsoft excel and GraphPad 5.0 software. The *P*-values were determined by two-tailed Student's *t*-test in a triplicate experiment representative of at least three independent experiments. Multiple comparisons were made using Kruskal-Wallis test. Significance was defined as **P* 0.05, ***P* 0.01. Results are presented as mean+ SD. Each biological replicate has at least 5 technical replicates.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported by grants from the National Institutes of Health, EY018636 (DS), EY019037 (DS) and EY01765 (Wilmer Imaging Core) and Research to Prevent Blindness (an unrestricted grant to The Wilmer Eye Institute). DS is a recipient of the Sybil B. Harrington Special Scholar award for Macular Degeneration from Research to Prevent Blindness. We would like to thank Drs. Akrit Sodhi and Xiaoban Xin for providing the adenoviral vectors and Dr. Raphael Kopan for N8E plasmids. We also thank Morton F Goldberg, Bidyut Ghosh and Seth Greenbaum for critically reading the manuscript.

References

1. Scheer N, Groth A, Hans S, Campos-Ortega JA. An instructive function for Notch in promoting gliogenesis in the zebrafish retina. *Development*. 2001; 128:1099–1107. [PubMed: 11245575]
2. Taylor MK, Yeager K, Morrison SJ. Physiological Notch signaling promotes gliogenesis in the developing peripheral and central nervous systems. *Development*. 2007; 134:2435–2447. [PubMed: 17537790]
3. Gaiano N, Nye JS, Fishell G. Radial glial identity is promoted by Notch1 signaling in the murine forebrain. *Neuron*. 2000; 26:395–404. [PubMed: 10839358]
4. Lundkvist J, Lendahl U. Notch and the birth of glial cells. *Trends Neurosci*. 2001; 24:492–494. [PubMed: 11506867]
5. Andersson ER, Sandberg R, Lendahl U. Notch signaling: simplicity in design, versatility in function. *Development*. 2011; 138:3593–3612. [PubMed: 21828089]
6. Spasic D, Annaert W. Building gamma-secretase: the bits and pieces. *J Cell Sci*. 2008; 121:413–420. [PubMed: 18256384]
7. Kopan R, Ijagan MX. The canonical Notch signaling pathway: unfolding the activation mechanism. *Cell*. 2009; 137:216–233. [PubMed: 19379690]
8. McGill MA, McGlade CJ. Mammalian numb proteins promote Notch1 receptor ubiquitination and degradation of the Notch1 intracellular domain. *J Biol Chem*. 2003; 278:23196–23203. [PubMed: 12682059]
9. Fortini ME. Notch signaling: the core pathway and its posttranslational regulation. *Dev Cell*. 2009; 16:633–647. [PubMed: 19460341]
10. Le Borgne R. Regulation of Notch signalling by endocytosis and endosomal sorting. *Curr Opin Cell Biol*. 2006; 18:213–222. [PubMed: 16488590]
11. Sorkin A, von Zastrow M. Endocytosis and signalling: intertwining molecular networks. *Nat Rev Mol Cell Biol*. 2009; 10:609–622. [PubMed: 19696798]
12. Vaccari T, Lu H, Kanwar R, Fortini ME, Bilder D. Endosomal entry regulates Notch receptor activation in *Drosophila melanogaster*. *J Cell Biol*. 2008; 180:755–762. [PubMed: 18299346]
13. Yan Y, Deneff N, Schupbach T. The vacuolar proton pump, V-ATPase, is required for notch signaling and endosomal trafficking in *Drosophila*. *Dev Cell*. 2009; 17:387–402. [PubMed: 19758563]
14. Sun-Wada GH, Wada Y, Futai M. Lysosome and lysosome-related organelles responsible for specialized functions in higher organisms, with special emphasis on vacuolar-type proton ATPase. *Cell Struct Funct*. 2003; 28:455–463. [PubMed: 14745137]
15. Vaccari T, Duchi S, Cortese K, Tacchetti C, Bilder D. The vacuolar ATPase is required for physiological as well as pathological activation of the Notch receptor. *Development*. 2010; 137:1825–1832. [PubMed: 20460366]
16. Piatigorsky, J. Gene sharing and evolution: the diversity of protein function. Harvard university press; Cambridge, MA: 2007.
17. Andley UP. Crystallins in the eye: Function and pathology. *Prog Retin Eye Res*. 2007; 26:78–98. [PubMed: 17166758]
18. Bhat SP. Transparency and non-refractive functions of crystallins—a proposal. *Exp Eye Res*. 2004; 79:809–816. [PubMed: 15642317]
19. Sinha D, et al. A spontaneous mutation affects programmed cell death during development of the rat eye. *Exp Eye Res*. 2005; 80:323–335. [PubMed: 15721615]
20. Ma B, et al. betaA3/A1-Crystallin controls anoikis-mediated cell death in astrocytes by modulating PI3K/AKT/mTOR and ERK survival pathways through the PKD/Bit1-signaling axis. *Cell Death Dis*. 2011; 2:e217. [PubMed: 21993393]
21. Givogri MI, et al. Notch signaling in astrocytes and neuroblasts of the adult subventricular zone in health and after cortical injury. *Dev Neurosci*. 2006; 28:81–91. [PubMed: 16508306]
22. Carlen M, et al. Forebrain ependymal cells are Notch-dependent and generate neuroblasts and astrocytes after stroke. *Nat Neurosci*. 2009; 12:259–267. [PubMed: 19234458]

23. Collier JR, Monk NA, Maini PK, Lewis JH. Pattern formation by lateral inhibition with feedback: a mathematical model of delta-notch intercellular signalling. *J Theor Biol.* 1996; 183:429–446. [PubMed: 9015458]
24. Sinha D, et al. betaA3/A1-crystallin in astroglial cells regulates retinal vascular remodeling during development. *Mol Cell Neurosci.* 2008; 37:85–95. [PubMed: 17931883]
25. Gehlbach P, et al. Developmental abnormalities in the Nuc1 rat retina: a spontaneous mutation that affects neuronal and vascular remodeling and retinal function. *Neuroscience.* 2006; 137:447–461. [PubMed: 16289888]
26. Rand MD, et al. Calcium depletion dissociates and activates heterodimeric notch receptors. *Mol Cell Biol.* 2000; 20:1825–1835. [PubMed: 10669757]
27. Benedito R, et al. The notch ligands Dll4 and Jagged1 have opposing effects on angiogenesis. *Cell.* 2009; 137:1124–1135. [PubMed: 19524514]
28. Sun X, Artavanis-Tsakonas S. Secreted forms of DELTA and SERRATE define antagonists of Notch signaling in *Drosophila*. *Development.* 1997; 124:3439–3448. [PubMed: 9310338]
29. Pannuti A, et al. Targeting Notch to target cancer stem cells. *Clin Cancer Res.* 2006; 16:3141–3152. [PubMed: 20530696]
30. Fortini ME, Bilder D. Endocytic regulation of Notch signaling. *Curr Opin Genet Dev.* 2010; 19:323–328. [PubMed: 19447603]
31. Pasternak SH, et al. Presenilin-1, nicastrin, amyloid precursor protein, and gamma-secretase activity are co-localized in the lysosomal membrane. *J Biol Chem.* 2003; 278:26687–26694. [PubMed: 12736250]
32. Frykman S, et al. Synaptic and endosomal localization of active gamma-secretase in rat brain. *PLoS One.* 2010; 5:e8948. [PubMed: 20126630]
33. Purow B. Notch inhibition as a promising new approach to cancer therapy. *Adv Exp Med Biol.* 2012; 727:305–319. [PubMed: 22399357]
34. Jehn BM, Dittert I, Beyer S, von der Mark K, Bielke W. c-Cbl binding and ubiquitin-dependent lysosomal degradation of membrane-associated Notch1. *J Biol Chem.* 2002; 277:8033–8040. [PubMed: 11777909]
35. Ge W, et al. Notch signaling promotes astroglial gene activation via direct CSL-mediated glial gene activation. *J Neurosci Res.* 2002; 69:848–860. [PubMed: 12205678]
36. Wohl SG, Schmeer CW, Isenmann S. Neurogenic potential of stem/progenitor-like cells in the adult mammalian eye. *Prog Retin Eye Res.* 2012; 31:213–242. [PubMed: 22353284]
37. Wechsler-Reya RJ, Barres BA. Retinal development: communication helps you see the light. *Current Biology.* 1997; 7:R433–R436. [PubMed: 9210366]
38. Stone J, Dreher Z. Relationship between astrocytes, ganglion cells and vasculature of the retina. *J Comp Neurol.* 1987; 255:35–49. [PubMed: 3819008]
39. Dorrell MI, Friedlander M. Mechanisms of endothelial cell guidance and vascular patterning in the developing mouse retina. *Prog Retin Eye Res.* 2006; 25:277–295. [PubMed: 16515881]
40. Lai EC. Notch signaling: control of cell communication and cell fate. *Development.* 2004; 131:965–973. [PubMed: 14973298]
41. Furukawa T, Mukherjee S, Bao ZZ, Morrow EM, Cepko CL. rax, Hes1, and notch1 promote the formation of Muller glia by postnatal retinal progenitor cells. *Neuron.* 2000; 26:383–394. [PubMed: 10839357]
42. Hojo M, et al. Glial cell fate specification modulated by the bHLH gene Hes5 in mouse retina. *Development.* 2000; 127:2515–2522. [PubMed: 10821751]
43. Sinha D, et al. β A3/A1-crystallin is required for proper astrocyte template formation and vascular remodeling in the retina. *Transgenic Research.* 2012; 21:1033–42. [PubMed: 22427112]
44. Zigler JS Jr. Mutation in the betaA3/A1-crystallin gene impairs phagosome degradation in the retinal pigmented epithelium of the rat. *J Cell Sci.* 2011; 124:523–531. [PubMed: 21266465]
45. Jefferies KC, Cipriano DJ, Forgac M. Function, structure and regulation of the vacuolar (H⁺)-ATPases. *Arch Biochem Biophys.* 2008; 476:33–42. [PubMed: 18406336]
46. Mindell JA. Lysosomal acidification mechanisms. *Annu Rev Physiol.* 2012; 74:69–86. [PubMed: 22335796]

47. Forgac M. Vacuolar ATPases: rotary proton pumps in physiology and pathophysiology. *Nat Rev Mol Cell Biol.* 2007; 8:917–929. [PubMed: 17912264]
48. Kornfeld S, Mellman I. The biogenesis of lysosomes. *Annu Rev Cell Biol.* 1989; 5:483–525. [PubMed: 2557062]
49. Yamamoto S, Charng WL, Bellen HJ. Endocytosis and intracellular trafficking of Notch and its ligands. *Curr Top Dev Biol.* 2010; 92:165–200. [PubMed: 20816395]
50. Muyrers JP, Zhang Y, Stewart AF. ET-cloning: Think recombination first. *Genet Eng.* 2000; 22:77–98.
51. Araki K, Araki M, Yamamura K. Negative selection with the diphtheria toxin A fragment gene improves frequency of cre-mediated cassette exchange in ES cells. *J Biochem.* 2006; 140:793–798. [PubMed: 17043056]
52. Auerbach W, et al. Establishment and chimera analysis of 129/svev-and c57bl/6-derived mouse embryonic stem cell lines. *Biotechniques.* 2000; 29:1024–1028. [PubMed: 11084865]
53. Mi H, Barres BA. Purification and characterization of astrocyte precursor cells in the developing rat optic nerve. *J Neurosci.* 1999; 19:1049–1061. [PubMed: 9920668]
54. Valapala M, Thamake SI, Viswanatha JK. A competitive hexapeptide inhibitor of annexin A2 prevents hypoxia-induced angiogenic events. *J Cell Sci.* 124:1453–1464. [PubMed: 21486955]
55. Parthasarathy G, et al. Expression of betaA3/A1-crystallin in the developing and adult rat eye. *J Mol Histol.* 2011; 42:59–69. [PubMed: 21203897]
56. Song W, et al. Proteolytic release and nuclear translocation of Notch-1 are induced by presenilin-1 and impaired by pathogenic presenilin-1 mutations. *Proc Natl Acad Sci U S A.* 1999; 96:6959–6963. [PubMed: 10359821]
57. Barriere H, et al. Revisiting the role of cystic fibrosis transmembrane conductance regulator and counterion permeability in the pH regulation of endocytic organelles. *Mol Biol Cell.* 2009; 20:3125–3141. [PubMed: 19420138]
58. Aubry L, Klein G, Satre M. Endo-lysosomal acidification in *Dictyostelium discoideum* amoebae. Effects of two endocytosis inhibitors: caffeine and cycloheximide. *Eur J Cell Biol.* 1993; 61:225–8. [PubMed: 7693471]
59. Cox BE, Griffin EE, Ullery JC, Jerome WG. Effects of cellular cholesterol loading on macrophage foam cell lysosome acidification. *J Lipid Res.* 2007; 48:1012–1021. [PubMed: 17308299]
60. Ilagan MXG, Lim S, Fulbright M, Piwnicka-Worms D, Kopan R. Real-time imaging of notch activation with a luciferase complementation-based reporter. *Sci Signal.* 2011; 4:rs7. [PubMed: 21775282]






Figure 1.


Levels of Notch1 and Jagged1 in immunopanned, postnatal day 2 WT and Nuc1 optic nerve astrocytes. **a, b.** Quantitative reverse transcriptase (qRT) PCR using Taqman expression probes shows that Notch1 was elevated by >2 fold in Nuc1 astrocytes (* $P=0.027$), relative to WT astrocytes. WT and Nuc1 astrocytes had similar levels of Jagged1. **c.** Western analysis for Jagged1 shows similar protein levels in WT and Nuc1 astrocytes. **d.** Retinal flat mounts from a 3-day old WT rat showing significant co-localization (yellow) of Jagged1 (red) with GFAP (green) positive astrocytes. **e, f.** Immunostaining and western analysis for active Notch (NICD) using anti-V1744 antibody shows that NICD was decreased by 76% in Nuc1 astrocytes compared to WT astrocytes (* $P=0.0031$). **g.** Expression and distribution of NICD and Jagged1 as revealed by immunostaining with anti-V1744 active Notch (red) and anti-Jagged1 antibodies (green). Decreased nuclear staining for NICD was evident in Nuc1 cells, but Jagged1 staining was similar in WT and Nuc1 astrocytes. Scale bar = 20 μm . In all panels, graphs show mean values and error bars represent s.d. from a triplicate experiment representative of at least three independent experiments. Statistical analysis was performed by a two-tailed Student's *t*-test: * $P < 0.05$.

**Figure 2.**


6XCBF-1 luciferase activity in WT and Nuc1 astrocytes transfected with Notch. **a.** In WT astrocytes transfected with the Notch-FL plasmid, luciferase activity in untreated astrocytes was significantly higher (4 fold increase) than in untreated vector transfected astrocytes (* $P=0.016$). Significant induction of luciferase activity was observed in the presence of EDTA in WT astrocytes expressing Notch-FL plasmid (* $P=0.031$), while luciferase activity was significantly reduced in the presence of the γ -secretase inhibitor, DAPT (* $P=0.009$) compared to untreated astrocytes. DMSO (vehicle for DAPT) alone did not affect expression significantly. Luciferase activity in WT astrocytes expressing the N5E construct was not increased by EDTA, but existing activity was inhibited by DAPT (* $P=0.012$). Vector transfected cells showed basal levels of luciferase activity. **b.** In Nuc1 astrocytes, transfected with the Notch-FL plasmid, there was no significant induction of luciferase activity in the presence of EDTA. Luciferase activity was significantly reduced in the presence of DAPT (* $P=0.025$) compared to untreated cells. Luciferase activity in Nuc1 astrocytes expressing N5E was not induced in the presence of EDTA but could be inhibited in the presence of DAPT(* $P=0.007$). Vector transfected cells showed basal levels of luciferase activity. **c, d.** qRT-PCR analysis for expression of Hes1 and Hey1 in WT and Nuc1 astrocytes. Nuc1 astrocytes showed about 65% and 75% reduction in the levels of Hes1 and Hey1, respectively, compared to WT astrocytes (* $P=0.030$ and * $P=0.027$ respectively). In all panels, graphs show mean values and error bars represent s.d. from a triplicate experiment representative of at least three independent experiments. Statistical analysis was performed by a two-tailed Student's t -test: * $P < 0.05$.

**Figure 3.**

Effect of Jagged1 on Notch signaling in WT and Nuc1 astrocytes **a**. Western analysis for Jagged1 in WT and Nuc1 astrocytes transfected with scrambled or ON-TARGET plus Smart pool Jagged1 siRNA. Downregulation of Jagged1 expression was observed in both WT and Nuc1 astrocytes transfected with the targeted siRNA. **b**. qRT-PCR for the Notch pathway targets, Hes1 and Hey1, in WT and Nuc1 astrocytes after treatment with scrambled or Jagged1 siRNA. Knockdown of Jagged1 expression (* $P=0.013$ in WT and * $P=0.017$ in Nuc1) is reflected by decreased expression of Hes1 (* $P=0.022$ in WT and * $P=0.015$ in Nuc1) and Hey1 (Right panel- values relative to scrambled siRNA in left panel). **c**. 12XCSL-luciferase reporter activity in co-cultures of Notch1-expressing astrocytes carrying 12XCSL-luciferase reporter construct (Δ EGF) or pRL-cmv control (EGF) construct, with astrocytes overexpressing the Jagged1 ligand. Graph shows luciferase activity (arithmetic mean) from triplicates of each co-culture. Robust luciferase activity was seen in WT astrocytes (* $P=0.011$), compared to Nuc1 astrocytes. This increase is compromised in astrocytes expressing the Jagged1 Δ EGF Notch-binding deficient plasmid. **d**. 12XCSL-luciferase reporter activity in co-cultures of Jagged1 knockdown astrocytes expressing 12XCSL-luciferase reporter construct or pRL-cmv control constructs with astrocytes overexpressing Jagged1. A marked induction of Notch signaling was observed in both WT (* $P=0.019$) and Nuc1 astrocytes transfected with Jagged1 siRNA (* $P=0.027$) and co-cultured with astrocytes over-expressing Jagged1 compared to scrambled siRNA treated cells (left panel). Astrocytes transfected with empty vector were also co-cultured with Jagged1 overexpressing cells, showing a modest induction of the Notch pathway in WT and none in Nuc1 homozygous astrocytes. In all panels, graphs show mean values and error bars represent s.d. from a triplicate experiment representative of at least three independent experiments. Statistical analysis was performed by a two-tailed Student's *t*-test: * $P < 0.05$.


**Figure 4.**

Proteolytic cleavage of Notch in WT and Nuc1 astrocytes. **a**. WT and Nuc1 astrocytes were treated with the metalloproteinase inhibitor BB-94 and expression of the Notch target genes, Hes1 and Hey1, determined by qRT-PCR. Expression of these genes was decreased to similar extent in WT (Hes-1* $P=0.031$ and Hey1* $P=0.022$) and Nuc1 astrocytes (Hes-1* $P=0.027$ and Hey1* $P=0.027$), (BB-94 relative to DMSO) **b**. Depiction of Notch plasmids (modified from Ilagan et. Al⁶⁰) used to define Notch cleavage. At top is shown the myc-tagged full length Notch (Notch-FL). NδE denotes the constitutively active, membrane-bound derivative of Notch1 that was produced by deletion of the EGF repeats. V1744K is the NδE-derived construct with a mutation at the Notch cleavage site (V1774K), preventing the cleavage and release of the NICD. ICv1744 is also an NδE-derived construct that is truncated at the cleavage site thereby generating only cleaved Notch. **c**. Nuc1 astrocytes were transfected with a Myc epitope-tagged, constitutively active Notch plasmid, NδE. Cells were also transfected with NδE (V1744K) with a mutation at the cleavage site generating a non-cleavable form of Notch, and with ICv1744, a truncated Notch plasmid that expresses only the cleaved form of Notch. Western analysis was performed with monoclonal anti-Myc antibody. The uncleaved (uc) and cleaved (c) forms of Notch were identified as bands corresponding to ~85 kDa and ~75 kDa respectively. Both the uc and c bands were identified in WT and Nuc1 astrocytes transfected with NδE. NδE (V1744K) and ICv1744 plasmids served as controls for the uc and c forms, respectively. In all panels, graphs show mean values and error bars represent s.d. from a triplicate experiment representative of at least three independent experiments. Statistical analysis was performed by a two-tailed Student's *t*-test: * $P < 0.05$.

**Figure 5.**

Nuclear translocation of active Notch **a**. WT and Nuc1 astrocytes transfected with the Notch intracellular domain (NICD) overexpression construct or vector control were immunoblotted with Notch anti-V1744 antibody to detect NICD. Elevated levels of NICD were seen in both WT and Nuc1 astrocytes transfected with the NICD overexpression construct compared to vector transfected astrocytes. **b**. Immunostaining of NICD-transfected and vector-transfected WT and Nuc1 astrocytes with Notch anti-V1744 antibody detected increased nuclear staining of NICD in NICD-transfected astrocytes compared to vector transfected astrocytes. Scale bar = 20 μ m. **c**. qRT-PCR to detect the expression levels of Hey1 and Hes1 in WT and Nuc1 astrocytes transfected with NICD or vector only. NICD-transfected Nuc1 astrocytes showed a rescue in the expression of both Hey1 and Hes1 (* $P=0.012$; * $P=0.017$ respectively). **d**, **e**. qRT-PCR to detect the expression levels of Hey1 and Hes1 in cells transfected with Notch full length (Notch-FL) showed increased expression of Hey1(* $P=0.026$; * $P=0.017$) and Hes-1(* $P=0.031$; * $P=0.017$) in WT astrocytes, but not in Nuc1 astrocytes. No changes in the expression of Hey1 and Hes1 were observed in both the cell types transfected with Notch Extracellular Truncation Domain (NEXT) plasmids. In all panels, graphs show mean values and error bars represent s.d. from a triplicate experiment

representative of at least three independent experiments. Statistical analysis was performed by a two-tailed Student's *t*-test: **P* < 0.05.

**Figure 6.**

Assessment of γ -secretase activity in WT and in astrocytes lacking β A3/A1-crystallin. **a.** Post-mitochondrial supernatants from WT and Nuc1 astrocytes were layered on 2.5–30% iodixanol gradients and subjected to ultracentrifugation. Western blots identified LAMP1-positive lysosomes in fractions 3, 4, and 5; Rab5-positive endosomes in fractions 6, 7, and 8; and Golgi in fractions 9 and 10. **b.** ELISA was performed to quantify β -amyloid ($A\beta$ 40) production after incubating above fractions overnight at 37°C, with or without L-685,458 (γ -secretase inhibitor). In WT astrocytes, γ -secretase activity, as measured by $A\beta$ 40 level, was detected in fractions 3, 4 and 5 (lysosomes), and in fractions 6, 7 and 8 (late and early endosomes). γ -secretase activity was detected at lower level in the Golgi (fractions 9 and 10). **c.** In Nuc1 astrocytes, γ -secretase activity was significantly decreased in the endolysosomal compartments (approximately 50% reduction), whereas the activity in Golgi was unchanged. **d.** Over-expression of β A3/A1-crystallin in astrocytes cultured from Nuc1 rats rescued γ -secretase activity in endolysosomal compartments, while empty vector had no

effect (relative to vehicle) **e.** Deletion of *Cryba1* from Nucl heterozygote astrocytes using a *Cryba1* ON-TARGET-plus SMART pool siRNA reduced γ -secretase activity in endolysosomal compartments substantially, to levels comparable to that of Nucl homozygote astrocytes. There was no effect on activity in Golgi. Over-expression of β A3/A1-crystallin in the same astrocytes as in **e**, rescued activity to control levels in the endolysosomal fractions. Scrambled siRNA had no effect (relative to vehicle). **f.** Astrocytes from *Cryba1*-floxed mice were infected with recombinant adenovirus (Ad) constructs (Ad CMV Cre-RSV GFP or Ad CMV-eGFP) followed by β A3/A1-crystallin over-expression. *Cryba1* knockout (Ad CMV Cre-RSV GFP) mouse astrocytes show markedly reduced γ -secretase activity in the endolysosomal compartments, with no effect on Golgi. Subsequent over-expression of β A3/A1-crystallin rescued activity to near normal levels in endolysosomal fractions (relative to *Cryba1* flox-Ad CMV-eGFP). In all panels, graphs show mean values and error bars represent s.d. from a triplicate experiment representative of at least three independent experiments. Statistical analysis was performed by a two-tailed Student's *t*-test: **P* < 0.05. ***P* < 0.01.




Figure 7.

Impaired V-ATPase activity in astrocytes lacking functional β 3/A1-crystallin **a.** V-ATPase activity was measured by acridine orange fluorescence in WT and Nuc1 astrocytes after intravesicular H^+ uptake was initiated by the addition of Mg-ATP. Increase in acridine orange fluorescence upon addition of ATP was significantly greater in WT astrocytes compared to Nuc1 astrocytes (* $P=0.017$). During the measurement of lysosomal pH, bafilomycin a1 was added to the ATP treated lysosomes for control purposes. **b.** In Nuc1 astrocytes, over-expression of β 3/A1-crystallin rescued activity to >80% of normal level (* $P=0.020$). Empty vector had no effect. **c.** V-ATPase activity in heterozygote astrocytes was significantly reduced by *Cryba1* siRNA knockdown (* $P=0.033$), but was rescued to normal levels when β 3/A1-crystallin was subsequently over-expressed in the same astrocytes (* $P=0.024$). **d.** In astrocytes from mice with floxed *Cryba1*, deletion of *Cryba1* by Cre-recombinase decreased V-ATPase activity relative to control astrocytes (* $P=0.018$). The V-ATPase activity was rescued to normal levels by subsequent over-expression of β 3/A1-crystallin in *Cryba1* knockout mouse astrocytes (* $P=0.027$). **e.** Measurement of endolysosomal pH in WT and Nuc1 astrocytes was performed using a fluid phase fluorescent probe, FITC-dextran. 3 hours after incubation of WT and Nuc1 astrocytes with FITC-dextran the fluorescence emission was measured at 520 nm with excitation at 450 nm and 495 nm. The fluorescence excitation ratio at 495 nm and 450 nm (I_{495nm}/I_{450nm}) was calculated, and endolysosomal pH in WT and Nuc1 astrocytes was measured to be ~4.5 and 5.7 respectively (* $P=0.031$). **f.** The elevated pH in Nuc1 homozygous astrocytes was restored to near normal acidic range by over-expression of β 3/A1-crystallin (* $P=0.026$). Empty vector had no effect. **g.** Further knockdown of β 3/A1-crystallin in Nuc1 heterozygote astrocytes by *Cryba1* siRNA elevated the endolysosomal pH to near Nuc1 homozygous levels (* $P=0.036$). Subsequent over-expression of β 3/A1-crystallin decreased pH to the level characteristic of WT astrocytes (* $P=0.021$). Scrambled siRNA had no effect. **h.** pH was elevated to near Nuc1 homozygote level in *Cryba1* knockout mouse astrocytes (* $P=0.029$) and was rescued to near normal levels by subsequent over-expression of β 3/A1-crystallin to same cells (* $P=0.024$). In all panels, graphs show mean values and error

bars represent s.d. from a triplicate experiment representative of at least three independent experiments. Statistical analysis was performed by a two-tailed Student's *t*-test: **P* < 0.05.




Figure 8.

Intracellular processing and degradation of Notch receptor **a.** WT and Nuc1 astrocytes transfected with myc-tagged full length Notch1 receptor were monitored for receptor clearance when co-cultured with astrocytes overexpressing Jagged1. Top panels show myc labeling (red) after transfection. Labeling decreased quickly in WT astrocytes, with little remaining after 3 hours. Degradation was minimal in the Nuc1 astrocytes. Scale bar = 20 μm . **b.** Subcellular fractionation showed Notch1 present in LAMP1-positive late endosomes/lysosomes (interface 1) and Rab5-positive early endosomes (interface 2) in both WT and Nuc1 astrocytes, but more strongly so in Nuc1. Over-expression of $\beta\text{A3/A1}$ -crystallin in Nuc1 astrocytes (right panel) stimulated Notch1 degradation, decreasing Notch1 to the range present in WT astrocytes. Notch1 was not present in endoplasmic reticulum (calnexin positive lane). **c.** Immunostaining of WT and Nuc1 astrocytes for $\beta\text{A3/A1}$ -crystallin (red), revealed abundant staining in the cytosol in both cell types. Co-localization (yellow) with LAMP1-positive lysosomes (green) was perinuclear in WT; little co-localization was seen in Nuc1 and lysosome distribution was abnormal. Scale bar=20 μm . **d.** Subcellular fractionation revealed both βA3 - and βA1 -crystallins in the cytosol of WT and Nuc1 astrocytes. They were more strongly associated with lysosomes (Interface 1) in WT astrocytes. **e.** Western analysis demonstrated substantially reduced levels of Cathepsin D heavy (~50%) and light (~60%) chains in Nuc1 homozygote astrocytes relative to WT, consistent with decreased active enzyme in the mutant astrocytes. Quantification as described in Methods. **f.** Over-expression of $\beta\text{A3/A1}$ -crystallin in Nuc1 astrocytes increased activity from 30% to 75% of WT level (* $P=0.037$). **g.** Cathepsin D activity in Nuc1 heterozygote astrocytes was decreased 80% by *Cryba1* siRNA knockdown of $\beta\text{A3/A1}$ -crystallin (** $P=0.011$); subsequent over-expression of $\beta\text{A3/A1}$ -crystallin rescued activity to control values (** $P=0.009$). **h.** In astrocytes from *Cryba1* floxed mice, deletion by Cre-recombinase reduced Cathepsin D activity (~60%) (* $P=0.031$); subsequent over-expression of $\beta\text{A3/A1}$ -crystallin rescued the activity (* $P=0.018$). **i.** Schematic model of Notch signaling

and β A3/A1-crystallin. Steps affected by loss of β A3/A1-crystallin shown by red dotted arrows. Impaired endolysosomal acidification inhibits Notch receptor processing and degradation, decreases NICD, ultimately reducing transcription of Notch target genes. In all panels, graphs show mean values and error bars represent s.d. from a triplicate experiment representative of at least three independent experiments. Statistical analysis was performed by a two-tailed Student's *t*-test: ** $P < 0.01$; * $P < 0.05$.